Adaptimmune Therapeutics plc Gains 49.18%
Wed, Oct 22, 2025 at 07:24 PM
Adaptimmune Therapeutics plc (ADAP:NASDAQ) rocketted at $0.07, representing a gain of 49.2%. The stock got featured on our News Catalysts scanner on Tue, Oct 21, 2025 at 02:00 AM in the 'INVESTOR UPDATE' category. From Wed, Oct 08, 2025, the stock recorded 50.00% Up Days and 36.36% Green Days
The stock spiked on Thu, Oct 09, 2025 at $0.28 with a volume of 247M+.
About Adaptimmune Therapeutics plc (ADAP:NASDAQ)
Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.
Top 10 Gainers:
- Beneficient (BENF:NASDAQ), 205.95%
- Connexa Sports Technologies Inc. (YYAI:NASDAQ), 133.75%
- Armata Pharmaceuticals, Inc. (ARMP:NYSEMKT), 103.17%
- Adaptimmune Therapeutics plc (ADAP:NASDAQ), 49.18%
- Applied DNA Sciences Inc. (BNBX:NASDAQ), 40.35%
- Kuke Music Holding Limited (KUKE:NYSE), 39.18%
- Noodles & Company (NDLS:NASDAQ), 33.02%
- Smart Logistics Global Limited (SLGB:NASDAQ), 30.67%
- Vicor Corporation (VICR:NASDAQ), 30.33%
- Winnebago Industries, Inc. (WGO:NYSE), 28.53%